title: [Arterial occlusion associated with interaction between ritonavir and ergotamine in HIV patient].
authors.forename: R
authors.initials: R
authors.lastname: Collado Borrell
authors.forename: S
authors.initials: S
authors.lastname: Sanz Márquez
authors.forename: M
authors.initials: M
authors.lastname: Pérez Encinas
mesh_terms: D000328:Adult; D000925:Anticoagulants / Q000627:therapeutic use; D001132:Arm / Q000098:blood supply; D001157:Arterial Occlusive Diseases / Q000139:chemically induced* / Q000188:drug therapy; D051544:Cytochrome P-450 CYP3A; D065692:Cytochrome P-450 CYP3A Inhibitors; D004338:Drug Combinations; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004878:Ergotamine / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D008658:Inactivation, Metabolic; D007511:Ischemia / Q000139:chemically induced* / Q000188:drug therapy; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology; D020326:Migraine without Aura / Q000150:complications / Q000188:drug therapy*; D019438:Ritonavir / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use; D015912:Thrombolytic Therapy; D014662:Vasoconstrictor Agents / Q000009:adverse effects* / Q000493:pharmacokinetics / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D065692:Cytochrome P-450 CYP3A Inhibitors; D004338:Drug Combinations; D017320:HIV Protease Inhibitors; D014662:Vasoconstrictor Agents; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D019438:Ritonavir; D004878:Ergotamine